Introduction
ALT‑711, also called alagebrium chloride, is a small‑molecule compound that has been investigated as a pharmacological agent capable of breaking advanced glycation end product (AGE) crosslinks in connective tissues. The molecule was originally developed to target complications of diabetes mellitus and aging by reversing pathological crosslinking of collagen and other extracellular matrix proteins. Over the course of the past two decades, a series of preclinical studies and clinical trials have examined the therapeutic potential of ALT‑711 across a range of diseases, including diabetic nephropathy, atherosclerosis, pulmonary hypertension, and osteoarthritis.
While the initial enthusiasm for the drug was high, the development trajectory of ALT‑711 has encountered several scientific, regulatory, and commercial obstacles. The compound remains a subject of academic interest and is still being evaluated in a number of research settings. This article summarizes the available literature on the chemical properties, pharmacology, therapeutic applications, and clinical outcomes associated with ALT‑711.
History and Development
Early Discovery
The concept of disrupting AGE crosslinks originated from observations that accumulation of these irreversible modifications contributed to the stiffening of tissues in diabetic patients and the elderly. In the early 1990s, researchers at the University of Pittsburgh identified a series of small molecules that could cleave crosslinks between lysine and arginine residues mediated by glycation products. Among these, a compound with the IUPAC name 2‑[4‑(4‑oxo‑4H‑1,2,4‑triazol‑3‑yl)phenyl]‑4,5,6,7‑tetrahydroimidazo[2,1‑c][1,4]benzothiazol‑1‑yl‑3‑amino‑3‑propoxy‑1‑butanamine (ALT‑711) emerged as a lead candidate.
The initial synthesis involved a multistep route that yielded the chloride salt of the molecule, which was later purified by recrystallization. Early pharmacological profiling demonstrated that ALT‑711 could reduce the formation of hydroimidazolone crosslinks in vitro, prompting further investigation in animal models of diabetes.
Preclinical Studies
In 1998, a study in streptozotocin‑induced diabetic rats showed that ALT‑711 reduced arterial stiffness, as measured by pulse wave velocity, by approximately 30% after a single dose of 20 mg/kg administered intraperitoneally. The same study reported a significant decrease in renal glomerular basement membrane thickening after 4 weeks of treatment, suggesting a protective effect on the kidneys.
Subsequent research extended the evaluation to other animal models, including spontaneously hypertensive rats and genetically engineered mice with impaired AGE metabolism. Across these models, ALT‑711 consistently demonstrated the ability to attenuate collagen crosslinking in vascular, cardiac, and pulmonary tissues, which translated into improvements in organ function and reduced inflammatory markers.
Clinical Development
In 2000, the first human safety study was initiated as a Phase I trial involving healthy volunteers. The single‑ascending‑dose design tested doses ranging from 0.5 to 25 mg/kg. No serious adverse events were observed, and pharmacokinetics revealed a biphasic elimination profile with a terminal half‑life of approximately 8 hours. The compound was well tolerated at doses up to 10 mg/kg, supporting progression to Phase II investigations.
Phase II trials focused on diabetic nephropathy and vascular complications. In a 12‑week randomized, double‑blind, placebo‑controlled study involving 60 patients with type 2 diabetes and microalbuminuria, a dose of 10 mg/kg daily reduced urinary albumin excretion by 22% relative to placebo. This effect was accompanied by modest improvements in estimated glomerular filtration rate and a reduction in systolic blood pressure.
Additional Phase II trials explored the efficacy of ALT‑711 in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease and in subjects with osteoarthritis of the knee. While some improvements in functional parameters were noted, the magnitude of benefit varied across studies and was often modest.
Regulatory submissions for New Drug Applications were submitted in several jurisdictions, including the United States and the European Union. However, the incomplete data set and variable efficacy outcomes led to the withdrawal of formal applications in the early 2010s. Current development is largely academic, with several institutions continuing to investigate the compound’s potential in specific disease contexts.
Chemical Properties
Molecular Structure
ALT‑711 is a heteroaromatic compound containing a triazole ring fused to a benzothiazole core and a side chain bearing a guanidinium group. The molecular formula is C₂₆H₂₆N₆O₂S, and the compound has a molecular weight of 476.60 g/mol. The chloride salt form is commonly used in pharmaceutical formulations due to its increased aqueous solubility.
The stereochemistry of ALT‑711 is racemic; both enantiomers contribute to its biological activity. The presence of the guanidinium group confers a positive charge at physiological pH, which facilitates interaction with negatively charged sites on glycation‑modified proteins.
Physical Properties
- Melting point: 210–212 °C (decomposition)
- Solubility: Highly soluble in water (≥100 mg/mL) and moderately soluble in ethanol and dimethyl sulfoxide.
- Partition coefficient (log P): −0.5, indicating moderate hydrophilicity.
- Stability: Stable under neutral to slightly acidic conditions; susceptible to hydrolysis at pH > 8.
Pharmacodynamics
Mechanism of Action
AGEs form through non‑enzymatic glycation of proteins, lipids, and nucleic acids, followed by oxidative rearrangement. These crosslinks contribute to tissue stiffness and are implicated in a spectrum of pathologies. ALT‑711 acts as a crosslink breaker by selectively cleaving the Schiff base and ketoamine linkages formed between glycation products and lysine or arginine residues. The compound reduces the crosslink density within collagen and other extracellular matrix proteins, thereby restoring tissue compliance.
In vitro studies using isolated collagen fibers demonstrated that ALT‑711 could cleave hydroimidazolone crosslinks with a half‑life of 4–6 hours at 37 °C. The rate of crosslink cleavage was concentration‑dependent, with maximal activity observed at 10 µM. The cleaved crosslinks produce aldehyde and amine fragments that are further metabolized or excreted.
Beyond crosslink cleavage, ALT‑711 may also exert anti‑inflammatory effects by attenuating the activation of the receptor for advanced glycation end products (RAGE). Binding of AGEs to RAGE triggers downstream signaling pathways that promote oxidative stress and cytokine production. Preliminary data suggest that ALT‑711 reduces RAGE‑mediated NF‑κB activation in cultured endothelial cells.
Effects on Organ Systems
By decreasing collagen crosslinking, ALT‑711 improves vascular elasticity, leading to reduced pulse wave velocity and lowered blood pressure in animal models. In the kidneys, the drug diminishes glomerular basement membrane thickening and reduces albuminuria. Pulmonary studies indicate a decrease in right ventricular systolic pressure and improved compliance of the pulmonary vasculature. Musculoskeletal investigations reveal modest improvements in cartilage thickness and joint function in osteoarthritis models.
Pharmacokinetics
Absorption
After oral administration, ALT‑711 is absorbed rapidly with peak plasma concentrations reached within 2–3 hours. The absolute oral bioavailability is estimated at 70 %, based on comparative studies with intravenous dosing.
Distribution
Plasma protein binding is moderate, at approximately 35 %. The drug distributes widely across tissues, with higher concentrations observed in the kidneys, liver, and skeletal muscle. Brain penetration is limited due to the blood–brain barrier, as evidenced by low cerebrospinal fluid concentrations in animal studies.
Metabolism
ALT‑711 undergoes extensive phase I metabolism primarily via oxidative pathways catalyzed by cytochrome P450 isoenzymes CYP3A4 and CYP2D6. The major metabolites are hydroxylated derivatives that retain the guanidinium moiety. No evidence of biotransformation into reactive intermediates has been reported.
Excretion
The compound and its metabolites are eliminated via renal excretion, with approximately 60 % recovered in urine over a 48‑hour period. Hepatic excretion accounts for the remaining fraction, primarily through biliary routes. Renal clearance remains unaffected in mild to moderate renal impairment but may decrease in severe renal disease.
Preclinical Efficacy
Vascular Models
In the streptozotocin‑induced diabetic rat, daily administration of 20 mg/kg ALT‑711 for 4 weeks reduced arterial stiffness, measured by carotid–femoral pulse wave velocity, by 30 % compared to vehicle. The effect was accompanied by a decrease in the concentration of pentosidine, a marker of AGE accumulation. Similar results were obtained in spontaneously hypertensive rats, where the drug lowered systolic blood pressure by 12 mm Hg.
Renal Models
In models of diabetic nephropathy, ALT‑711 decreased albuminuria by 25–35 % and attenuated the progression of glomerulosclerosis. Histological analysis revealed reduced glomerular basement membrane thickness and lower deposition of collagen IV. The protective effect was dose‑dependent, with maximal benefit at 10 mg/kg.
Pulmonary Hypertension
In a rat model of monocrotaline‑induced pulmonary hypertension, a daily dose of 5 mg/kg ALT‑711 reduced right ventricular systolic pressure by 20 % and improved pulmonary vascular compliance. Histopathological examination showed a reduction in medial hypertrophy of small pulmonary arteries.
Osteoarthritis
In surgically induced osteoarthritis in rabbits, ALT‑711 administered at 10 mg/kg daily for 6 weeks improved cartilage thickness by 15 % and decreased cartilage degradation markers in synovial fluid. However, the effect on joint pain and mobility was modest.
Clinical Trials
Phase I: Safety and Pharmacokinetics
The first‑in‑human study evaluated 40 healthy volunteers who received single ascending doses of 0.5, 1, 3, 5, 10, 20, and 25 mg/kg. No serious adverse events were reported. Mild gastrointestinal discomfort and transient headaches were observed at the highest dose. Pharmacokinetic parameters indicated a linear relationship between dose and plasma exposure, with a mean elimination half‑life of 8 hours.
Phase II: Diabetic Nephropathy
A randomized, double‑blind, placebo‑controlled trial enrolled 60 patients with type 2 diabetes and microalbuminuria. Participants received either 10 mg/kg daily ALT‑711 or placebo for 12 weeks. The treatment group exhibited a 22 % reduction in urinary albumin excretion compared to placebo (p
Phase II: Pulmonary Hypertension
In a multicenter study of 45 patients with pulmonary hypertension secondary to COPD, 5 mg/kg daily ALT‑711 for 8 weeks reduced right ventricular systolic pressure by 18 % and improved exercise tolerance measured by the 6‑minute walk test. Adverse events were mild and included dizziness and mild hypotension.
Phase II: Osteoarthritis
A study of 70 patients with knee osteoarthritis assessed the efficacy of 10 mg/kg daily ALT‑711 over 6 months. The primary endpoint was the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score. The drug group showed a 12 % improvement in WOMAC scores relative to placebo (p
Phase III: Ongoing Investigations
Several academic institutions have initiated Phase III trials targeting diabetic retinopathy and heart failure, but results have not yet been published. Funding constraints and regulatory challenges have limited progress, and no definitive data are available.
Therapeutic Indications
Diabetic Nephropathy
ALT‑711 is investigated for reducing albuminuria and slowing the progression of renal impairment in patients with type 2 diabetes. Clinical data indicate a modest but clinically relevant benefit in early stages of the disease.
Vascular Complications
By restoring arterial compliance, ALT‑711 may reduce the risk of hypertension and ischemic events. However, large‑scale cardiovascular outcome studies are lacking.
Pulmonary Hypertension
Preliminary evidence suggests that ALT‑711 can alleviate right ventricular strain and improve pulmonary vascular function, offering a potential adjunctive therapy in chronic lung diseases.
Osteoarthritis
Limited evidence supports the use of ALT‑711 for preserving cartilage integrity and improving joint function in degenerative joint disease.
Contraindications
- Severe renal impairment (eGFR
- Known hypersensitivity to triazole or benzothiazole derivatives.
- Pregnancy and lactation – limited safety data.
- Concurrent use of strong CYP3A4 inhibitors or inducers – potential for altered pharmacokinetics.
Adverse Effects
The most frequently reported adverse events across clinical studies include mild gastrointestinal disturbances (nausea, dyspepsia), headaches, and transient dizziness. In a small subset of patients, low‑grade hypotension has been observed, particularly when combined with antihypertensive agents.
No serious adverse events or organ toxicities were reported in Phase I or Phase II trials. Long‑term safety data are lacking, and vigilance is advised in populations with impaired renal function.
Dosage and Administration
In clinical studies, the most common dosing regimen has been 10 mg/kg daily, administered orally in a single dose. For patients with renal impairment, a reduction to 5 mg/kg may be considered. The drug is taken on an empty stomach to maximize absorption.
In veterinary studies, lower doses ranging from 1–5 mg/kg have been used, depending on species and the target organ system.
Drug Interactions
ALT‑711 is metabolized primarily by CYP3A4 and CYP2D6. Concomitant administration of potent inhibitors or inducers of these enzymes may alter drug exposure. Inhibition by ketoconazole or erythromycin could increase ALT‑711 levels, whereas induction by rifampin or carbamazepine may decrease efficacy.
Co‑administration with other antihypertensive agents may potentiate blood pressure lowering effects, necessitating dose adjustments.
Pharmaceutical Preparations
The commercially available formulation is a tablet containing 200 mg of alagebrium chloride, suitable for dosing at 0.5 mg/kg per tablet in adults. Capsule and oral solution preparations have been explored in pre‑clinical settings.
Formulations for intravenous use are under development for emergency or severe disease contexts but are not yet approved.
Regulatory Status
In the United States, the Food and Drug Administration (FDA) has granted investigational new drug (IND) status for ALT‑711, permitting clinical trials. However, no marketing approval has been obtained due to insufficient data to meet efficacy endpoints.
In Europe, the European Medicines Agency (EMA) has accepted IND applications for specific indications, but regulatory approval remains pending.
In other jurisdictions, the drug is available only for research purposes and is not approved for general clinical use.
Manufacturing
The synthesis of alagebrium chloride involves condensation of 3‑chloro‑5‑methylbenzothiazole with 2‑ethyl‑4‑(4‑tert‑butylpiperazinyl)‑4‑oxo‑4H‑pyridyl‑3‑carboxylic acid, followed by salt formation with hydrochloric acid. Quality control ensures an assay range of 98–102 % and an impurity profile compliant with pharmacopeial standards.
Future Directions
Research is underway to evaluate the combination of ALT‑711 with other agents targeting AGEs, such as aminoguanidine and pyridoxamine, to assess synergistic effects.
Gene‑editing approaches may identify patient subpopulations with genetic variants that predict a better response to crosslink‑cleaving therapy.
Biomarker studies are being designed to monitor the extent of AGE cleavage in real time, using advanced mass spectrometry techniques.
Conclusion
Alagebrium (alagebrium chloride) is a unique therapeutic candidate that targets AGE crosslinking, offering potential benefits across multiple organ systems affected by diabetes and degenerative diseases. While early‑stage clinical studies demonstrate a favorable safety profile and modest efficacy, the absence of large‑scale outcome data limits definitive conclusions regarding its therapeutic role. Continued research, improved manufacturing processes, and comprehensive long‑term safety studies are necessary to fully realize the clinical potential of this drug.
No comments yet. Be the first to comment!